Bifidobacterium breve M-16V and Developed Cow's Milk Tolerance

• Tolerance development in cow's milk-allergic infants receiving amino acid-based formula: A randomized controlled trial.

  • 2022-02
  • RCT · n = 89
  • The Journal of allergy and clinical immunology 149(2)
  • • Pantipa Chatchatee
    • Anna Nowak-Wegrzyn
    • Lars Lange
    • Suwat Benjaponpitak
    • Kok Wee Chong
    • Pasuree Sangsupawanich
    • Marleen T J van Ampting
    • Manon M Oude Nijhuis
    • Lucien F Harthoorn
    • Jane E Langford
    • Jan Knol
    • Karen Knipping
    • Johan Garssen
    • Valerie Trendelenburg
    • Robert Pesek
    • Carla M Davis
    • Antonella Muraro
    • Mich Erlewyn-Lajeunesse
    • Adam T Fox
    • Louise J Michaelis
    • Kirsten Beyer

  • PubMed: 34224785
  • DOI: 10.1016/j.jaci.2021.06.025

  1 Insight on

  • Developed Cow's Milk Tolerance

  • High evidence
  • Infants

  At 12 and 24 months, respectively, 49% and 62% of subjects were CM tolerant (AAF-S 45% and 64%; AAF 52% and 59%), and not differ significantly between groups.

  Effect

  Neutral

  Effect size

  Small

  Significant

  No